A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Ibrutinib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 19 May 2017 Planned End Date changed from 1 Jul 2016 to 1 Nov 2017.
- 19 May 2017 Planned primary completion date changed from 1 Mar 2016 to 1 Aug 2017.
- 08 Sep 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.